Atezolizumab,Cabozantinib
Roche
['rcc,(-irccs),(-srcc),(-urcc)', 'atezo']
evidence-based answer to the problematic 2l in mrcc after io failure:
io(atezo) rechallenge does not improve outcomes and increases toxicity when compared with cabo
clinically crucial results and mesmerizing presentation #asco23 
Postdoctoral GU Oncology Research Fellow @DanaFarber | MD '2021, MSc '2019 @USJLiban 🏎️🎾📖